Drug profile · INN
methylergonovine maleate
METHYLERGONOVINE MALEATE
methylergonovine maleate (METHYLERGONOVINE MALEATE) is a serotonin 2b (5-ht2b) receptor partial agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — methylergonovine maleate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
methylergonovine maleate (METHYLERGONOVINE MALEATE) is a serotonin 2b (5-ht2b) receptor partial agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2b (5-HT2b) receptor partial agonist
Primary target: D(1A) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is methylergonovine maleate?
methylergonovine maleate (METHYLERGONOVINE MALEATE) is a serotonin 2b (5-ht2b) receptor partial agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for methylergonovine maleate?
METHYLERGONOVINE MALEATE is a marketed brand name for methylergonovine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylergonovine maleate?
methylergonovine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.